Editorial - Advances in Oncolytic Antitumour Adenoviral Therapies: Three Key Aspects

C. Fillat
{"title":"Editorial - Advances in Oncolytic Antitumour Adenoviral Therapies: Three Key Aspects","authors":"C. Fillat","doi":"10.2174/1875037001003010008","DOIUrl":null,"url":null,"abstract":"Oncolytic virotherapy based on adenoviral vectors is an intensive area of research and many advances are being conducted with the general aim to come up with full potential oncolytic adenoviruses to be effective in the human clinical context. Two main concepts are driving the genetic engineering of adenoviruses. On one hand there are the strategies directed towards enhancing the viral potency and on the other those that focus on adenoviral selectivity. This special issue reviews current research on adenoviral oncolysis by focusing on three key aspects in adenoviral biology: viral entrance to the cell, viral replication, and viral exit from the cell. The first review \" Targeting adenoviral entry to enhance oncolytic antitumor response \" discusses on the effectiveness of pseudotyping, genetic targeting or the use of adaptor molecules to enter adenovirus into tumor cells. It also summarizes the effects of detargeting adenovirus from their natural tropism, of special interest in systemic applications to treat disseminated disease. The second review \" Controlling adenoviral replication to induce oncolytic efficacy \" discusses on the broad number of genetic elements that are being engineer into the adenoviral genome to control replication. And how the increased knowledge on the specific behavior and regulation of neoplastic cells and tumor microenvironment can be exploited to develop novel oncolytic adenoviruses. The third review \" Adenovirus release from the infected cell as a key factor for adenoviral oncolysis \" summarizes the strategies used to facilitate adenoviral spreading into the tumor by favoring the release from the infected cells. In a first term it reviews the biology of adenoviral release. This special issue highlights the hot-topic aspects in the expanding field of adenoviral oncolysis where many new and exciting developments are rapidly being generated. which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.","PeriodicalId":88328,"journal":{"name":"The open gene therapy journal","volume":"3 1","pages":"8-8"},"PeriodicalIF":0.0000,"publicationDate":"2013-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open gene therapy journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875037001003010008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Oncolytic virotherapy based on adenoviral vectors is an intensive area of research and many advances are being conducted with the general aim to come up with full potential oncolytic adenoviruses to be effective in the human clinical context. Two main concepts are driving the genetic engineering of adenoviruses. On one hand there are the strategies directed towards enhancing the viral potency and on the other those that focus on adenoviral selectivity. This special issue reviews current research on adenoviral oncolysis by focusing on three key aspects in adenoviral biology: viral entrance to the cell, viral replication, and viral exit from the cell. The first review " Targeting adenoviral entry to enhance oncolytic antitumor response " discusses on the effectiveness of pseudotyping, genetic targeting or the use of adaptor molecules to enter adenovirus into tumor cells. It also summarizes the effects of detargeting adenovirus from their natural tropism, of special interest in systemic applications to treat disseminated disease. The second review " Controlling adenoviral replication to induce oncolytic efficacy " discusses on the broad number of genetic elements that are being engineer into the adenoviral genome to control replication. And how the increased knowledge on the specific behavior and regulation of neoplastic cells and tumor microenvironment can be exploited to develop novel oncolytic adenoviruses. The third review " Adenovirus release from the infected cell as a key factor for adenoviral oncolysis " summarizes the strategies used to facilitate adenoviral spreading into the tumor by favoring the release from the infected cells. In a first term it reviews the biology of adenoviral release. This special issue highlights the hot-topic aspects in the expanding field of adenoviral oncolysis where many new and exciting developments are rapidly being generated. which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
社论-溶瘤性抗肿瘤腺病毒治疗的进展:三个关键方面
基于腺病毒载体的溶瘤病毒治疗是一个密集的研究领域,许多进展正在进行,其总体目标是充分发挥溶瘤腺病毒在人类临床环境中的作用。驱动腺病毒基因工程的主要有两个概念。一方面是针对增强病毒效力的策略,另一方面是针对腺病毒选择性的策略。本期特刊回顾了目前腺病毒肿瘤分解的研究,重点介绍了腺病毒生物学的三个关键方面:病毒进入细胞、病毒复制和病毒退出细胞。第一篇综述“靶向腺病毒进入增强溶瘤抗肿瘤反应”讨论了假分型、基因靶向或使用接头分子进入腺病毒进入肿瘤细胞的有效性。它也从腺病毒的自然趋向性总结了去靶向性腺病毒的作用,特别感兴趣的是在系统应用治疗播散性疾病。第二篇综述“控制腺病毒复制以诱导溶瘤效应”讨论了大量的遗传元件被设计到腺病毒基因组中以控制复制。以及如何利用对肿瘤细胞和肿瘤微环境的具体行为和调节的了解来开发新的溶瘤腺病毒。第三篇综述“从感染细胞中释放腺病毒是腺病毒溶瘤的关键因素”综述了通过有利于从感染细胞中释放腺病毒来促进腺病毒向肿瘤扩散的策略。第一学期,它回顾了腺病毒释放的生物学。本期特刊重点介绍了腺病毒肿瘤学领域的热点问题,其中许多新的和令人兴奋的发展正在迅速产生。允许在任何媒介上不受限制地、非商业地使用、分发和复制,只要作品被适当地引用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信